Modafinil Aurobindo

Modafinil, the active ingredient in Modafinil Aurobindo, is a eugeroic presented as an oral tablet for oral use. It promotes wakefulness and is prescribed for excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder.

GNH USA supplies Modafinil Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modafinil acts on central nervous system pathways that regulate wakefulness, making it useful for several sleep‑related disorders. - Narcolepsy: reduces excessive daytime sleepiness and improves alertness in patients with narcolepsy. - Obstructive sleep apnea: alleviates residual daytime sleepiness when used alongside standard apnea therapy. - Shift work disorder: helps workers maintain alertness during atypical work hours.

Modafinil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate pain often reported during early treatment. - Nausea: transient gastrointestinal discomfort. - Insomnia: difficulty falling or staying asleep when taken later in the day. - Anxiety: heightened nervousness or restlessness. - Dry mouth: reduced salivation. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Psychiatric events: including hallucinations, mania, or severe depression. - Cardiovascular complications: hypertension, arrhythmia, or chest pain. - Hypersensitivity: anaphylaxis or angioedema. - Hepatic injury: elevated liver enzymes or hepatitis.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor for adverse events. - Cardiovascular assessment: check blood pressure and cardiac history. - Hypersensitivity screening: avoid in patients with known allergy to modafinil. - Psychiatric monitoring: watch for new or worsening mental health symptoms. - Hepatic function: use caution and consider dose adjustment in liver impairment. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Modafinil can affect the metabolism of several co‑administered drugs, requiring attention to potential interactions.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce modafinil exposure. - Hormonal contraceptives: modafinil can lower contraceptive effectiveness, increasing pregnancy risk. - Monoamine oxidase inhibitors: concurrent use may precipitate hypertensive crises.

Moderate Interactions (Monitor Closely): - Caffeine and other stimulants: may amplify central nervous system stimulation. - Selective serotonin reuptake inhibitors: increased risk of insomnia or anxiety. - Antihypertensive agents: possible reduction in blood‑pressure‑lowering effect.